NCT04629729 2026-03-19FT819 in Subjects With B-cell MalignanciesFate TherapeuticsPhase 1 Active not recruiting54 enrolled
NCT04155710 2025-12-24Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLLIovance Biotherapeutics, Inc.Phase 1 Completed7 enrolled
NCT05400122 2025-11-12Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in CancerCase Comprehensive Cancer CenterPhase 1 Suspended12 enrolled
NCT07225439 2025-11-06Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)Case Comprehensive Cancer CenterPhase 1 Not yet recruiting15 enrolled